Anti Gd1a Igg Antibody Positivity C5676715
An immune response where IgG antibodies target GD1a gangliosides on nerves. May indicate ongoing or past autoimmune nerve damage, requiring monitoring and possible immunosuppression.
Key facts at a glance
- ICD-10
- G43.909
- ICD-11
- 8A00.0
- Body system
- neurologic
- Severity
- severe
- Chronic
- false
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Limb weakness
Respiratory distress
Generalized symptoms
(neurologic)Significant symptoms that substantially affect daily functioning.
Frequency: Varies
Absent deep tendon reflexes
(neurologic)Facial weakness
(neurologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Intravenous Immunoglobulin (IVIG)
IVIG is the standard first-line therapy for IgG-mediated anti-ganglioside neuropathies. It works by blocking pathogenic antibody binding, inhibiting complement activation, and modulating cytokine production to reduce nerve inflammation.
Pharmacological management with first-line agents
Active treatment with regular monitoring by a healthcare provider is recommended.
Therapeutic Apheresis
Plasma exchange or immunoadsorption apheresis selectively removes pathogenic IgG antibodies from circulation. This procedure is effective for severe or rapidly progressive disease and can be combined with immunoglobulin replacement.
Additional treatment options
Rituximab
Rituximab is a monoclonal antibody targeting CD20 on B cells, reducing production of pathogenic IgG antibodies. It is considered for refractory cases or when conventional immunosuppression fails.
medicationComprehensive Rehabilitation
Individualized physical therapy focusing on strength preservation, sensory integration, and functional recovery. Therapy includes stretching to prevent contractures, strengthening exercises, and balance training.
physical_therapyClinical and Laboratory Surveillance
Combined clinical assessment and serial anti-ganglioside antibody titers to monitor disease activity. Regular neurological examinations complement laboratory testing for comprehensive monitoring.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Anti Gd1a Igg Antibody Positivity C5676715?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
van der Meche FGA, Jacobs BC, van Doorn PA. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of Guillain-Barre syndrome. Eur J Neurol. 2021.
Willison HJ, Goodyear CS. Glycolipid antigens and autoantibodies in autoimmune neuropathies. Trends Immunol. 2018.
Koga M, Yuki N, Hirata K. Anti-ganglioside antibody profiles in Miller Fisher syndrome and related disorders. J Neurol Sci. 2017.
Kaida K, Ariga T, Yu RK. Antiganglioside antibodies and their pathophysiological effects on Guillain-Barre syndrome and related disorders. Clin Rev Allergy Immunol. 2019.
Medication Comparisons
Compare medications used to treat Anti Gd1a Igg Antibody Positivity C5676715. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy